An observational study in Nemaline Myopathy, Myopathies and Myopathic Conditions, sponsored by Hospital Universitari Vall d'Hebron Research Institute. Recruiting at 1 site in Spain. Per ClinicalTrials.gov, last updated 2026-03-23.
Sponsored by Hospital Universitari Vall d'Hebron Research Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Muscular Diseases with a site in Spain — 10 open to participants now, 12 under way, 3 of them phase 3. Muscular Diseases · Spain.
Among the 24 studies in Muscular Diseases with a site in Spain, this one is one of 4 that started in 2026, is one of 7 observational ones, reaches primary completion later than 10 of the 11 other live ones, and was the 21st registered.
232 studies on the registry are indexed under Muscular Diseases; 54 are open to participants now.
Browse Muscular Diseases studies →10 of the 24 studies in Muscular Diseases with a site in Spain are open now. Recruiting first, the newest first:
RyCarma Therapeutics, Inc. · Sites in Spain, France, Germany and 2 more countries
Ages 18–65
Avidity Biosciences, Inc. · Sites in Spain, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
AstraZeneca · Sites in Spain, United States, Argentina and 32 more countries
Ages 5–80
AstraZeneca · Sites in Spain, United States, Canada and 7 more countries
Ages 18–70
Hospital de Mataró · Sites in Spain
Ages 18–75
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 38 Muscular Diseases studies recruiting now, 21 (55%) set no upper age limit and 10 (26%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 8
First in 2011; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 100 is close to the median of 95 across 85 observational studies indexed under Muscular Diseases.
Median enrollment 60 across the 17 interventional studies, 100 across the 7 observational. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 24 have an industry lead sponsor. The 10 most frequent:
Hospital Universitari Vall d'Hebron Research Institute is the lead sponsor of 276 studies on the registry; 63 are open to participants now.
Hospital Universitari Vall d'Hebron Research Institute has 1 study filed under Muscular Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Muscular Diseases with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
| NCT07560020RyCarma Therapeutics, Inc.A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy | 2027-08-27 |
| NCT05650229Pharming Technologies B.V.Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 24 studies in Muscular Diseases with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this natural history study is to comprehensively characterize the disease progression and clinical features of nemaline myopathies. The study aims to establish a well-defined cohort of patients in Spain, enabling long-term follow-up and facilitating recruitment for future clinical trials.
The aims of the study are:
Characterize the natural history of NM through the systematic collection of clinical (retrospective and prospective data), functional, and respiratory data in diagnosed patients in order to:
Patients with a confirmed clinical and genetic diagnosis of MN (mutations in ACTA1, NEB, TPM2, TPM3, KBTBD13, CFL2, KLHL40, KLHL41, LMOD3, MYPN, TNNT1, TNNT3), or under discussion if they only have a compatible biopsy.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with a confirmed clinical and genetic diagnosis of MN (mutations in ACTA1, NEB, TPM2, TPM3, KBTBD13, CFL2, KLHL40, KLHL41, LMOD3, MYPN, TNNT1, TNNT3), or under discussion if they only have a compatible biopsy
Diagnostic Test: Muscle Ultrasound · Diagnostic Test: Motor function scales · Other: Complete physical examination · Other: Ventilatory/ respiratory, Cardiac and other support assessment · Other: QOL assessment, Neuropsychological · Device: Digital Biomarkers · Other: Oromotor function and nutrition · Other: Motor Milestone Assessments
Ultrasound guided evaluation of 28 muscles evaluated accross different body regions, assessed using the Heckmatt gradinf system (semiquantitative scale).
Evaluation of patients motor function using motor scales (CHOP-INTEND, MFM32, HINE-2, NSAA, PDSM-3, RFF, 10m walk, PUL)
Complete physical evaluations including muscle power and goniometry measurements
Assessment of ventilatory, cardiac, nutritional, and other support needs
Assessment of quality of life
Video/photos with the aim is to record actions such as lifting a glass, raising arms above the head, getting up from the floor or a chair, walking, or running, in order to later analyze in detail how these movements are performed.
Assessment of bulbar funcionality: feeding devices, nutritional status.
Motor milestones age of acquisition and loss (if applicable)
Observe changes in muscle echogenicity by muscle ultrasound.
A standardized muscle ultrasound protocol of assessment is performed (whole body). Muscle images are scored using the Heckmatt scale (score 1-4): * Heckmatt grade 1 represents a normal muscle image. * Heckmatt grade 2 shows an increased echogenicity without attenuation of the deeper image regions. * Heckmatt grade 3 indicates a larger increase in echogenicity with some visible loss of normal muscle architecture. * Heckmatt grade 4 shows a strongly increased echogenicity with complete loss of recognizable muscle architecture.
Time frame: Change from baseline through study completion, an average of 5 years
Observe natural history changes in motor function using the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND)
The CHOP-INTEND assesses a child's ability to move their body in a lying down position, supported sitting, and assisted rolling through 16 items. Scores range from 0 to 64, with higher scores indicating better motor function. Change in motor function assessed using age-appropriate validated motor scales and dependent on patient's ability.
Time frame: Change from baseline through study completion, an average of 5 years
Observe natural history changes in motor function using the Hammersmith Infant Neurological Examination Section 2 (HINE-2)
This is a 37-item measure of infant developmental motor milestones that will be performed in participants aged 0-24months. Scores are interpreted in relation to optimality scores and cut-off scores for the participant's age. Higher scores represented higher function.
Time frame: Change from baseline through study completion, an average of 5 years
Observe natural history changes in Peabody Developmental Motor Scales (PDMS-3) Scale Score
Change in motor function assessed using age-appropriate validated motor scales and dependent on patient's ability. PDMS-3 measures various motor abilities in young children. Four types of normative scores are yielded: age equivalents, percentile ranks, subtest scaled scores, and composite index scores. Higher scores indicate higher level of function.
Time frame: Change from baseline through study completion, an average of 5 years
Observe natural history changes in motor function using the Motor Function Measure (MFM32) Scale Score
Change in motor function assessed using age-appropriate validated motor scales and dependent on patient's ability. This motor function assessment consists of 32 items organized in three dimensions: standing position and transfers, axial and limb proximal motor function, and limb distal motor function. Total scores are given between 0-100, with 0 indicating severe functional impairment and 100 indicating no functional impairment.
Time frame: Change from baseline through study completion, an average of 5 years
Observe natural history changes in motor function using the North Star Ambulatory Assessment (NSAA) score
Change in motor function assessed using age-appropriate validated motor scales and dependent on patient's ability. Scores in the NSAA scale range from 0 to 34, with higher scores indicating better motor function.
Time frame: Change from baseline through study completion, an average of 5 years
Observe natural history changes in the Performance of Upper Limb (PUL) score
Change in upper limb function assessed using the Performance of Upper Limb (PUL) scale. Higher scores indicate better function.
Time frame: Change from baseline through study completion, an average of 5 years
Observe the natural clinical progression in respiratory function.
Respiratory function will be assessed longitudinally using age-appropriate measures depending on patient ability. Respiratory status will include ventilatory support requirements (none, non-invasive ventilation, or invasive ventilation) and time on/off ventilator, when feasible. Forced vital capacity (FVC), expressed as percent predicted for age and sex, will be used when spirometry is possible.
Time frame: Change from baseline through study completion, an average of 5 years
Observe changes in Nutritional Status
Assessment of nutritional status over time through indicators such as feeding method (oral versus enteral feeding) and need for nutritional support. Swallowing status and dietary modifications will be recorded when applicable. Changes from baseline will be analyzed to evaluate nutritional progression and feeding outcomes.
Time frame: Change from baseline through study completion, an average of 5 years
Observe changes in Quality of Life
Assessment of patient or caregiver-reported quality of life using validated questionnaires appropriate for age and functional status, including standardized health-related quality of life instruments (the Clinical Global Impression-Severity \[CGI-S\], the Clinical Global Impression-Change \[CGI-C\], Patient Global Impression of Change \[PGI-C\], and Patient Global Impression of Severity \[PGI-S\]). Total scores and domain-specific scores will be analyzed. Changes from baseline will be evaluated to assess perceived health status and daily functioning.
Time frame: Change from baseline through study completion, an average of 5 years
Start is estimated for Jun 2026; primary completion for Jun 2031, 60 months later.
Of 36 observational studies under Muscular Diseases, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 159. This study's planned 60 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Universitari Vall d'Hebron Research Institute →